2.75
-0.22(-7.41%)
Currency In USD
| Previous Close | 2.97 |
| Open | 3.12 |
| Day High | 3.12 |
| Day Low | 2.75 |
| 52-Week High | 8.87 |
| 52-Week Low | 2.43 |
| Volume | 401,797 |
| Average Volume | 329,095 |
| Market Cap | 105.36M |
| PE | -1.66 |
| EPS | -1.66 |
| Moving Average 50 Days | 3.7 |
| Moving Average 200 Days | 5.22 |
| Change | -0.22 |
If you invested $1000 in Orchestra BioMed Holdings, Inc. (OBIO) since IPO date, it would be worth $241.23 as of May 02, 2025 at a share price of $2.75. Whereas If you bought $1000 worth of Orchestra BioMed Holdings, Inc. (OBIO) shares 3 years ago, it would be worth $276.66 as of May 02, 2025 at a share price of $2.75.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Orchestra BioMed Receives FDA Approval of IDE to Initiate U.S. Coronary Pivotal Trial Randomizing First-in-Class Sirolimus-AngioInfusion Balloon, Virtue SAB, Head-to-Head with Paclitaxel-Coated Balloon
GlobeNewswire Inc.
Apr 29, 2025 1:00 PM GMT
Orchestra BioMed’s Virtue® Sirolimus AngioInfusion Balloon™ (“Virtue SAB”) is the only non-coated drug-eluting balloon system under clinical investigation worldwide and has been awarded multiple FDA Breakthrough Device DesignationsThe Virtue Trial wi
Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences
GlobeNewswire Inc.
Apr 28, 2025 8:30 PM GMT
NEW HOPE, Pa., April 28, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships,
Orchestra BioMed Announces AVIM Therapy-Focused Satellite Symposium at HRS 2025 Annual Meeting
GlobeNewswire Inc.
Apr 23, 2025 1:00 PM GMT
FDA recently granted Breakthrough Device Designation to AVIM therapy for use in patients with uncontrolled hypertension at increased cardiovascular riskHRS Satellite Symposium will feature leading experts in electrophysiology, hypertension management